ADVA wins two MEF 3.0 Proof of Concept Awards
ADVA (FSE: ADV) today announced that it has jointly won two awards at the MEF 3.0 Proof of Concept (PoC) Showcase. The honors recognize innovation and leadership with emerging services and technologies involving AI, SD-WAN, service automation and more. The Judge’s Choice Award for the best overall PoC was presented to a multi-vendor solution using ADVA’s Ensemble NFV suite to deliver personalized and automatically generated live video content over optimized network slices. Leveraging AI video technology and uCPE hosting SD-WAN, the demo showed how service providers can meet demand for unique immersive experiences of events such as live sports. ADVA also won the Market Game Changer Award, recognizing the largest potential impact on the service provider market. This was presented for its collaboration on a PoC using ADVA Ensemble software to enable multi-edge cloud services. This technology will be key to empowering enterprises to provide low-latency, high-throughput applications such as smart factories and industrial IoT.
“Our award-winning demo, Revolutionizing Live Events, illustrates how cable network operators can deliver exciting new services in an entirely original way. We’ve shown that it’s now possible to offer a unique, differentiated experience of live events that puts audiences at the heart of the action. Sports or music fans could soon be selecting their own viewing angles and receiving coverage that automatically zooms and tracks in real time. And for service providers, this points to a simple and cost-effective way of enabling high-volume, high-margin entertainment services,” said James Buchanan, GM, Edge Cloud, ADVA. “We’ve shown that utilizing uCPE and network slicing over enterprise networks can transform the way video content is produced and distributed. This cloud-based, virtualized approach opens the door to new levels of flexibility and automation for video services. What’s more, it highlights the potential of uCPE as a platform for innovation ready to unleash an array of new applications and business models.”
Featuring ADVA’s Ensemble suite of NFV software, the Revolutionizing Live Events PoC highlighted new opportunities for service providers to meet the growing expectations of sports and entertainment audiences. Driven by compute-based AI/ML, MEF-defined network slicing and lightweight uCPE running SD-WAN, the demo showed how network resources can be utilized to provide automated, highly personalized video content.
ADVA’s other award-winning PoC was the Orchestrated Multi-Edge Clouds demo. For this, the Ensemble NFV suite was deployed to manage and orchestrate SD-WAN, IoT, 5G networking and other edge-cloud technologies, seamlessly enabling the distribution of smart manufacturing resources between on-premises and network edge cloud environments. This demo paves the way for enterprises to purchase mission-critical applications and services flexibly and on demand.
“Our multi-edge cloud MEF 3.0 PoC is a key step in helping businesses to improve operational efficiency as they continue to digitize and automate their processes. It shows how service providers can accelerate adoption of multi-edge cloud services through the orchestration of applications and connectivity on open edge compute platforms. Winning the Market Game Changer Award underlines the impact on enterprises of being able to instantly purchase applications such as IoT, SD-WAN and wireless network access from a single managed service provider and have them automatically deployed across multiple cloud platforms,” commented Mike Heffner, VP, product line management, Edge Cloud, ADVA. “Using our Ensemble NFV software, this PoC proves that it’s now possible to relieve businesses of the responsibility and burden of multi-vendor system integration. This creates a major opportunity for service providers. They can offer on-demand, managed edge services and connectivity on open edge compute platforms that can be deployed in multiple locations. And, using advanced analytics, they can select the best edge location for IoT applications to meet SLAs.”
More information about the Revolutionizing Live Events PoC is available here: https://adva.li/mef-poc-live-events.
Further details on the Orchestrated Multi-Edge Clouds demo can be viewed here: https://adva.li/mef-poc-multi-edge-clouds.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005482/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
